Antiretroviral Adherence and Pharmacogenetic Differences on HIV Treatment Outcomes

  • Botswana
  • |
  • Brazil
  • |
  • Haiti
  • |
  • Peru
  • |
  • South Africa
  • |
  • Uganda
  • |
  • Zambia
  • |
  • Zimbabwe

Dr. Gross designed and is co-chair of an international study (Botswana, Brazil, Haiti, Peru, Uganda, Zambia, Zimbabwe, South Africa) testing partner-based directly observed therapy in first treatment failures. His methods work is focused on the use of pharmacy refill measures of antiretroviral adherence and he has refined this approach over the last several years. Dr. Gross also has a research program ongoing in Botswana where he has an NIMH R01-funded cohort study of the impact of pharmacogenetic differences on HIV treatment outcomes. The aim is to determine whether pharmacogenetic information can be used to tailor antiretroviral therapy to the individual for better outcomes.